Golimumab and malignancies: True or false association?

Medical Oncology

Volumn 28, Issue 2, 2011, Pages 641-648

  Zidi, Ines ^a   Bouaziz, Aicha ^a   Mnif, Wissem ^a   Bartegi, Aghleb ^a   Ben Amor, Nidhal ^a  

^a UNIVERSITY OF MONASTIR   (Tunisia)

Author keywords

Anti TNF alpha; Cancer; Golimumab; Methotrexate

Indexed keywords

CORTICOSTEROID; GOLIMUMAB; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; ARTICLE; BASAL CELL CARCINOMA; BENIGN TUMOR; BLADDER CANCER; BREAST CANCER; COLON CANCER; DERMATOFIBROMA; HODGKIN DISEASE; HUMAN; LIP CARCINOMA; LIPOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; META ANALYSIS; OVARY TUMOR; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; THYROID TUMOR;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; METHOTREXATE; NEOPLASMS;

EID: 79960317391     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9490-7     Document Type: Article

References (57)

1. G Krueger K Callis 2004 Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis Arch Dermatol 140 218 225 14967799 10.1001/archderm.140.2.218 1:CAS:528:DC%2BD2cXhvF2ltbo%3D (Pubitemid 38500336)
2. LW Moreland JR Curtis 2008 Systemic nonarticular manifestations of rheumatoid arthritis: focus on inflammatory mechanisms Semin Arthritis Rheum 39 132 143 19022481 10.1016/j.semarthrit.2008.08.003
3. E Dommasch JM Gelfand 2009 Is there truly a risk of lymphoma from biologic therapies? Dermatol Ther 22 418 430 19845719 10.1111/j.1529-8019.2009. 01258.x
4. C Ferrandiz JM Carrascosa A Boada 2010 A new era in the management of psoriasis? The biologics: facts and controversies Clin Dermatol 28 81 87 20082956 10.1016/j.clindermatol.2009.03.002
5. JS Smolen ME Weinblatt 2008 When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step? Ann Rheum Dis 67 1497 1498 18854512 10.1136/ard.2008.098111
6. Food and Drug Administration. Center for drug evaluation and research, Chemistry review(s). FDA web site on line. 2009. http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2009/125289s000-ChemR.pdf.
7. G Hutas 2008 Golimumab, a fully human monoclonal antibody against TNF-alpha Curr Opin Mol Ther 10 393 406 18683105 1:CAS:528:DC%2BD1cXhtV2mtLbO
8. J Netterwald 2009 TNF-blocker triple approval Nat Biotechnol 27 6 495 19513037 10.1038/nbt0609-495 1:CAS:528:DC%2BD1MXntVWjur4%3D
9. J Kay, et al. 2008 Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate Arthritis Rheum 58 964 975 18383539 10.1002/art.23383 1:CAS:528:DC%2BD1cXltFGisbw%3D (Pubitemid 351563997)
10. P Emery, et al. 2009 Golimumab, a human anti-tumor necrosis factor monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of Golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis Arthritis Rheum 60 8 2272 2283 19644849 10.1002/art.24638 1:CAS:528:DC%2BD1MXhtV2hsLvJ
11. EC Keystone, et al. 2009 Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy : the GO-FORWARD Study Ann Rheum Dis 68 789 796 19066176 10.1136/ard.2008.099010 1:CAS:528:DC%2BD1MXotVCjtL0%3D
12. JS Smolen, et al. 2009 Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial Lancet 374 210 221 19560810 10.1016/S0140-6736(09)60506-7 1:CAS:528:DC%2BD1MXos12ru7o%3D
13. AD Pappas, et al. 2009 Golimumab Nat Rev Drug Discov 8 695 696 19721444 10.1038/nrd2982 1:CAS:528:DC%2BD1MXhtVKmsrzJ
14. V Oldfield GL Plosker 2009 Golimumab in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis Biodrugs 23 2 125 135 19489653 10.2165/00063030-200923020-00005 1:CAS:528:DC%2BD1MXovFSnsbk%3D
15. A Kavanaugh, et al. 2009 Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in Psoriatic Arthritis : twenty-Four-Week efficacy and safety results of a randomized, placebo-controlled study Arthritis Rheum 60 4 976 986 19333944 10.1002/art.24403 1:CAS:528:DC%2BD1MXltFenu7g%3D
16. Z Xu, et al. 2009 Population pharmacokinetics of Golimumab, an anti-tumor necrosis factor-α human monoclonal antibody, in patients with psoriatic arthritis J Clin Pharmacol 49 1056 1070 19617465 10.1177/0091270009339192 1:CAS:528:DC%2BD1MXhtFChu7vL
17. RD Inman, et al. 2008 Efficacy and safety of Golimumab in patients with ankylosing spondylitis: results of a randomized, double-Blind, placebo-controlled, phase III trial Arthritis Rheum 58 11 3402 3412 18975305 10.1002/art.23969 1:CAS:528:DC%2BD1cXhsV2hs7nL
18. SA Antoniu 2009 Golimumab for severe asthma Expert Opin Investig Drugs 18 9 1421 1423 19678804 10.1517/13543780903136716 1:CAS:528:DC%2BD1MXpslOlur8%3D
19. M Gaga E Zervas P Chanez 2009 Update on severe asthma: what we know and what we need Eur Respir Rev 18 58 65 20956126 10.1183/09059180.00001009 1:STN:280:DC%2BC3cbgtlOhtA%3D%3D
20. SE Wenzel, et al. 2009 A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma Am J Respir Crit Care Med 179 7 549 558 19136369 10.1164/rccm.200809-1512OC 1:CAS:528:DC%2BD1MXkslWnsLo%3D
21. Food and Drug Administration. Highlights of prescribing information. FDA web site on line. 2009. www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 125289s006lbl.pdf.
22. Shealy D, et al. Characterization of golimumab (CNTO 148), a novel fully human monoclonal antibody specific for human TNF alpha. Ann Rheum Dis. 2007;66 (Suppl 2):ii151.
23. Zidi I, Mestiri S, Bartegi B, Ben Amor N. TNF-alpha and its inhibitors in cancer. Med Oncol. 2009. doi: 10.1007/s12032-009-9190-3.
24. R Saraceno S Chimenti 2008 How to manage infections in the era of biologics? Dermatol Ther 21 180 186 18564248 10.1111/j.1529-8019.2008.00189.x (Pubitemid 351832370)
25. DA Hussar 2009 Newdrugs: golimumab, besifloxacin hydrochloride, and artemether/lumefantrine J Am Pharm Assoc 49 4 570 574 10.1331/JAPhA.2009.09523
26. T Bongartz, et al. 2006 Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials JAMA 295 2275 2285 16705109 10.1001/jama.295.19.2275 1:CAS:528:DC%2BD28Xksl2ktrk%3D (Pubitemid 43736578)
27. S Setoguchi, et al. 2006 Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis Arthritis Rheum 54 9 2757 2764 16947774 10.1002/art.22056 1:CAS:528:DC%2BD28XhtFWksLjO (Pubitemid 44497754)
28. P Dewan, et al. 2009 Melanoma in patients with rheumatoid arthritis treated with antitumour necrosis factor: cause or coincidence? Report of two cases Br J Dermatol 161 1412 1414 19785619 10.1111/j.1365-2133.2009.09465.x 1:STN:280:DC%2BD1MjosFSitw%3D%3D
29. F Wolfe K Michaud 2007 Biologic treatment of rheumatoid arthritis and the risk of malignancy Arthritis Rheum 56 9 2886 2895 17729297 10.1002/art.22864 (Pubitemid 47502734)
30. A Kornbluth 1998 Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference Inflamm Bowel Dis 4 328 329 9836088 10.1002/ibd.3780040415 1:STN:280:DyaK1M%2Flt1yjug%3D%3D
31. E Mahe, et al. 2003 CD30 + T-cell lymphoma in patient with psoriasis treated with ciclosporin and infliximab Br J Dermatol 149 170 173 12890213 10.1046/j.1365-2133.2003.05384.x 1:STN:280:DC%2BD3szlslOmtQ%3D%3D (Pubitemid 36966529)
32. A Nyfors H Jensen 1983 Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics. A preliminary study Dermatologica 167 260 261 6653851 10.1159/000249793 1:STN:280:DyaL2c%2FosFemug%3D%3D (Pubitemid 14239780)
33. C Salliot D van der Heijde 2009 Methotrexate monotherapy in rheumatoid arthritis patients. A systematic literature research Ann Rheumatic Dis 68 1100 1104 10.1136/ard.2008.093690 1:CAS:528:DC%2BD1MXovVCmsr4%3D
34. F Wolfe K Michaud 2004 Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18, 572 patients Arthritis Rheum 50 1740 1751 15188349 10.1002/art.20311 1:CAS:528: DC%2BD2cXlsFaqt7Y%3D (Pubitemid 38725085)
35. P Geborek, et al. 2005 Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may ba associated with an increased risk of lymphomas Ann Rheum Dis 64 699 703 15695534 10.1136/ard.2004.030528 1:CAS:528:DC%2BD2MXksFWrurc%3D (Pubitemid 40559295)
36. J Askling, et al. 2005 Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists Ann Rheum Dis 64 1421 1426 15829572 10.1136/ard.2004.033993 1:STN:280: DC%2BD2MvptFCisw%3D%3D (Pubitemid 41623851)
37. M Rozenblit M Lebwohl 2009 New biologics for psoriasis and psoriatic arthritis Dermatol Ther 22 56 60 19222517 10.1111/j.1529-8019.2008.01216.x
38. ER Soriano J Rosa 2009 Update on the treatment of peripheral arthritis in psoriatic arthritis Curr Rheumatol Rep 11 270 277 19691930 10.1007/s11926-009- 0038-9 1:CAS:528:DC%2BC3cXhtFeku7vL
39. CE Antoni, et al. 2008 Two-year efficacy and safety of Infliximab treatment in patients with active psoriatic arthritis: findings of the Inliximab Multinational psoriatic arthritis controlled trial (IMPACT) J Rheumatol 35 869 876 18381786 1:CAS:528:DC%2BD1cXntVOmurY%3D (Pubitemid 351747130)
40. Mease PJ, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol. 2006;33:712-721.
41. PJ Mease, et al. 2009 Adalimumab for long-term treatment of psoriasis arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT) Ann Rheum Dis 68 702 709 18684743 10.1136/ard.2008.092767 1:CAS:528:DC%2BD1MXls1Chu78%3D
42. JC Davis, et al. 2003 Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis : a randomized, controlled trial Arthritis Rheum 48 3230 3236 14613288 10.1002/art.11325 1:CAS:528:DC%2BD3sXpvVygtb0%3D (Pubitemid 37409337)
43. D Van der Heijde, et al. 2005 Efficacy and safety of Infliximab in patients with ankylosing spondylitis: results of a randomized, placebo controlled-trial (ASSERT) Arthritis Rheum 52 582 591 15692973 10.1002/art.20852 (Pubitemid 40216323)
44. D Van der Heijde, et al. 2006 Efficacy and safety of adalimumab in patients with ankylosing spondylitis : results of a multicenter, randomized, double-blind, placebo-controlled trial Arthritis Rheum 54 2136 2146 16802350 10.1002/art.21913 (Pubitemid 44051069)
45. H Zhou, et al. 2007 Pharmacokinetics and safety of Golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with Rheumatoid Arthritis J Clin Pharmacol 47 383 396 17322150 10.1177/0091270006298188 1:CAS:528:DC%2BD2sXjsVyjt78%3D (Pubitemid 46294717)
46. Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis Cochrane Database of Systematic Reviews 2010. Art. No.: CD008341(1). doi:[ 10.1002/14651858.CD008341.
47. Food and Drug Administration. Information on Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi) FDA ALERT [8/4/2009]. FDA web site on line. 2009. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm174474.htm.
48. RB Cohen KA Dittrich 2001 Anti-TNF therapy and malignancy- a critical review Can J Gastroenterol 15 6 376 384 11429667 1:STN:280: DC%2BD3Mznt1CrsQ%3D%3D (Pubitemid 32684665)
49. Food and Drug Administration. Center for drug evaluation and research, Summary review. FDA web site on line. 2009. http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2009/125289s000-SumR.pdf.
50. Food and Drug Administration. Center for drug evaluation and research, Office director memo. FDA web site on line. 2009. http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2009/125289s000-OD.Memo.pdf.
51. L Naldi 2010 Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies Clin Dermatol 28 88 92 20082957 10.1016/j.clindermatol.2009.03.003
52. Matera MG, Calzetta L, Cazzola M. TNF-alpha inhibitors in asthma and COPD: We must not throw the baby out with the bath water. Pulm Pharmacol Ther. 2009. doi: 10.1016/j.pupt.2009.10.007.
53. Furst DE, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis. 2008;67:iii2-iii25.
54. X Mariette, et al. 2002 Lymphomas in rheumatoid arthritis patients treated with methotrexate : a 3-year prospective study in France Blood 99 11 3909 3915 12010788 10.1182/blood.V99.11.3909 1:CAS:528:DC%2BD38XktFyrsrg%3D (Pubitemid 35332027)
55. JH Stone, et al. 2006 Solid malignancies among patients in the Wegener's Granulomatosis Etanercept trial Arthritis Rheum 54 5 1608 1618 16646004 10.1002/art.21869 1:CAS:528:DC%2BD28XlsFWjsrs%3D
56. BE Van den Born, et al. 1998 No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis Arthritis Rheum 41 1930 1937 10.1002/1529-0131(199811)41:11<1930::AID-ART6>3.0.CO;2- N (Pubitemid 28506681)
57. Kremer J, et al. Golimumab, a new human anti-TNFα antibody, administered intravenously in patients with active rheumatoid arthritis: 48-week efficacy and safety results of a phase 3, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2010. doi: 10.1002/art.27348.